Supply issues cause Takeda to drop manufacturing of Natpar/Natpara
Japan’s largest drugmaker Takeda (TYO: 4502) says that it will discontinue manufacturing its injectable parathyroid hormone Natpar/Natpara globally at the end of 2024 due to unresolved supply issues that are specific to the product.
As a result, Takeda will not re-commercialize the horm one in the USA, where it uses the brand name Natpara, and will discontinue manufacturing Natpar globally. Natpar/Natpara came to Takeda via its $62 billion acquisition of UK-based Shire.
Until the end of 2024, Takeda’s key priority is to maintain treatment continuity for patients who are currently receiving Natpar/Natpara, subject to available supply. This includes those enrolled in the US Special Use Program and all patients receiving Natpar in Europe and other regions around the world. Beyond 2024, Takeda intends to supply available doses until inventory is depleted or expired.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze